This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEI120U6_L.jpg
CAPE TOWN (Reuters) – South Africa’s Afrigen Biologics has used the publicly available sequence of Moderna (NASDAQ:MRNA)’s COVID-19 mRNA vaccine to make its own version of the shot, which could be tested in humans before the end of this year, Afrigen’s top executive said on Thursday.
The vaccine candidate would be the first to be made based on a widely used vaccine without the assistance and approval of the developer. It is also the first mRNA vaccine designed, developed and produced at lab scale on the African continent.
The World Health Organization (WHO) last year picked a consortium including Afrigen for a pilot project to give poor and middle-income countries the know-how to make COVID-19 vaccines, after market leaders of the mRNA COVID vaccine, Pfizer (NYSE:PFE), BioNTech and Moderna, declined a WHO request to share their technology and expertise.
The WHO and partners hope the hub will help overcome glaring inequalities between rich nations and poorer countries in accessing vaccine doses, with 99% of all of Africa’s vaccines imported and the negligible remainder manufactured locally.
During the pandemic, wealthy countries have hoovered up most of the world’s supplies of vaccines.
Biovac, a partly state-owned South African vaccine producer, will be the first recipient of the technology from the hub. Afrigen has also agreed to help train companies in Argentina and Brazil.
In September, the WHO’s hub in Cape Town decided to go it alone after failing to bring on board Pfizer and Moderna, both of which have argued they need to oversee any technology transfer due to the complexity of the manufacturing process.
Moderna’s vaccine was chosen due to an abundance of public information and its pledge not to enforce patents during the pandemic. It’s not clear what will happen after that.
The U.N.-backed Medicines Patent Pool (NASDAQ:POOL) (MPP) said it was in talks with Moderna about possible access to some of its patents
Under pressure to make drugs in lower-income countries, Moderna and BioNTech have announced plans to build mRNA vaccine factories in Africa, but production is still a long way off.
Biovac has agreed to fill and finish the Pfizer-BioNTech vaccine, the final stages of production, although the drug substance will come from Europe.
“We haven’t copied Moderna, we’ve developed our own processes because Moderna didn’t give us any technology,” Petro Terblanche, managing director at Afrigen told Reuters.
“We started with the Moderna sequence because that gives, in our view, the best starting material. But this is not Moderna’s vaccine, it is the Afrigen mRNA hub vaccine,” Terblanche said.
She said it had managed to make, in collaboration with Johannesburg’s University of the Witwatersrand, its first micro-litre laboratory scale batches of COVID-19 mRNA vaccines at the Cape Town facility.
Terblanche said it was working on a next generation mRNA vaccine that didn’t need freezing temperatures for storage, required for the Pfizer and Moderna doses, and which would be better suited to the hot conditions of Africa with its poor health facilities and infrastructure.
Afrigen was recruiting staff and receiving training from international partners including Thermo Fisher Scientific (NYSE:TMO), she said.
“We will only make our clinical trial batch probably in six months from now, (meaning) … fit for humans. And the target is November 2022,” Terblanche added.
Online training for other companies to make the shot started with manufacturers in Brazil and Argentina last year. Afrigen expects to get more on board within the next month.
